Table of Contents
In a combined analysis of three double-blind, placebo-controlled trials with 171 healthy adults, researchers found that microdosing psilocybin raised the proportion of original ideas people generated without increasing how many ideas they produced overall. Convergent problem-solving was unaffected.
- Quality over quantity: Microdosing raised the ratio of original to conventional ideas, but did not make participants faster or more prolific brainstormers.
- Convergent thinking unchanged: The ability to identify a single correct answer to a logic problem was not improved by the microdose, consistent with what the researchers predicted.
- Body weight matters: Exploratory analyses suggested that relative dose per kilogram of body weight predicted originality scores, implying a standard microdose may be insufficient for heavier individuals.
- Effects are real but fragile: The originality benefit held up after controlling for placebo expectation, yet one of the three individual trials failed to replicate the result on its own, signaling the effect is subtle and context-sensitive.
- Model
- human
- Sample
- 171 healthy adults across three trials (59, 61, and 27 participants respectively)
- Dose
- Approximately 0.65 g, 1 g, or 1.5 g of fresh psilocybin truffles, depending on the trial
- Design
- Three separate double-blind, placebo-controlled longitudinal trials; data pooled in a mega-analysis
- Key outcome
- Higher originality-to-fluency ratio in the microdosing condition; no effect on convergent thinking or idea fluency
- Main limitation
- Fresh truffle dosing lacks chemical precision; blinding broke down at the highest dose; second trial did not replicate on its own
What the Research Examined
This is a mega-analysis drawing on data from three separate double-blind, placebo-controlled trials conducted by a team led by Luisa Prochazkova at Leiden University and published in the journal Neuropharmacology. Across the three experiments, 171 healthy adults participated in workshops where they prepared their own capsules containing either dried psilocybin truffles or a non-psychoactive placebo. Neither participants nor researchers knew who received the active substance until the study concluded. Cognitive testing was scheduled to coincide with the expected peak effects of the microdose.
The doses varied by trial: roughly 0.65 grams of fresh truffles in the first experiment, about 1 gram in the second, and 1.5 grams in a crossover design in the third, where each participant experienced both conditions in separate blocks. Creativity was assessed through two established frameworks: divergent thinking, tested by asking participants to list as many uses as possible for a common object, and convergent thinking, tested by asking them to identify the single word linking three unrelated terms. The researchers calculated not just how many ideas participants generated (fluency) but the proportion of those ideas that were genuinely uncommon (the originality-to-fluency ratio). For anyone wanting broader context on what the science currently says about microdosing psilocybin research, the evidence base is still developing and this study adds meaningful nuance to it.
Because no single trial was large enough to detect subtle cognitive shifts with confidence, the team pooled all three datasets into one mega-analysis, arriving at 171 participants total. They also ran exploratory analyses examining whether relative dose per kilogram of body weight predicted outcomes, and whether the results held after statistically adjusting for participants who correctly guessed their condition, which was a concern particularly in the highest-dose trial.
What the Findings Show
- Originality-to-fluency ratio.In the pooled mega-analysis, participants in the active microdosing condition produced a statistically higher proportion of original ideas relative to total responses compared to those taking placebo.
- Fluency (total idea count).The total number of ideas generated during divergent thinking tasks did not differ significantly between the microdosing and placebo groups.
- Convergent thinking.Performance on tasks requiring identification of a single correct answer was not meaningfully different between the active and placebo conditions.
- Body weight and dose.Exploratory analyses found that psilocybin dose relative to body weight predicted unweighted originality scores, suggesting a fixed standard microdose may fall below an effective threshold for heavier participants.
The originality benefit survived a check for placebo expectation: even after the researchers statistically accounted for participants who correctly guessed they had received the active capsule, the improvement in idea quality remained present. This is meaningful because it reduces the likelihood that the effect was driven purely by participants believing they were more creative. That said, the second individual trial, using a mid-range dose, did not on its own reach statistical significance, which the authors acknowledge as a sign that the effect is real but modest and potentially sensitive to environmental or individual factors.
Does microdosing psilocybin improve creativity, and if so in what way?
Research from a pooled analysis of three placebo-controlled trials suggests microdosing psilocybin may improve the originality of ideas rather than how many ideas a person generates. Problem-solving that requires a single correct answer was not affected. Effects were modest and require further investigation.
What This Is, and What It Is Not
This is This is a mega-analysis of three controlled human trials involving 171 healthy adults screened for mental health conditions, testing standard creativity proxies in a semi-naturalistic laboratory setting.
This is not This is not evidence that microdosing psilocybin treats any condition, enhances real-world artistic or scientific output, or is appropriate for everyone. People with predispositions to psychosis or already highly flexible cognitive styles were not studied. Nothing here constitutes medical advice.
Our Take
Within the Church of Psychedelics, we have always understood the sacrament to work subtly, clearing away the worn grooves of habitual thought rather than flooding the mind with raw output. This study puts numbers to something many in contemplative communities have sensed: that a gentle relationship with psilocybin does not manufacture creativity from nothing, but may help the mind wander past its own cliches toward something less expected. The researchers frame this through neuroscience as the relaxation of hierarchical constraints in the brain. We might simply say the sacrament invites the mind to listen a little more openly. The science and the spiritual framing are not in conflict here; they are, perhaps, describing the same quiet opening from different vantage points.
If you find yourself drawn to understand how a practice of intentional, small-dose work might relate to your own creative or contemplative life, we welcome you to explore what the growing body of research actually shows, with honesty about what it does not yet show. The Grounding and Integration stations of the Golden Path exist precisely for moments like this, when curiosity stirs and discernment matters. Take your time with the findings. Let them settle before you reach for conclusions. That patience is itself a form of wisdom the sacrament tends to reward.
Frequently Asked Questions
What is the originality-to-fluency ratio and why does it matter?
It measures the proportion of uncommon ideas in a person’s total responses. A higher ratio means more of the ideas generated were original, not just that the person produced more ideas. This study found microdosing raised that ratio without increasing total idea count.
Did microdosing psilocybin help with problem-solving that has one correct answer?
No. Convergent thinking, the ability to identify a single correct answer linking unrelated words, was not improved in the active microdosing condition compared to placebo across the pooled analysis of all three trials.
Could the creativity improvement just be a placebo effect?
The researchers tested for this. After statistically controlling for participants who correctly guessed they received the active dose, the improvement in idea originality remained statistically meaningful, which reduces but does not fully eliminate the possibility of expectation effects.
Why might the results differ between heavier and lighter participants?
Exploratory analyses found that dose relative to body weight predicted originality scores. A standard fixed microdose may not produce the same cognitive shift in a heavier person, suggesting personalized dosing could be important in future research designs.
Is microdosing psilocybin safe based on this study?
No serious adverse events were reported among the healthy, screened participants in these three trials. However, the study was not designed to assess safety broadly and did not include people with mental health vulnerabilities. This finding should not be taken as a general safety endorsement.
Get the Mycelium Report
We read the new psilocybin and mushroom research so you do not have to. One honest, jargon-free dispatch, delivered daily. Free to join.
May love guide the hearts of all beings.
